Takeda Pharmaceutical Company (4502) Q4 2025 earnings summary

Executive summary

• FY2024 saw 2.8% core revenue growth at constant exchange rate and 7.5% reported revenue growth, driven by a 14.7% increase in growth and launch products, now 48% of total core revenue, offsetting VYVANSE generic erosion.

• Core operating profit grew 4.9% at constant exchange rate, with margin at 25.4%, up 65 bps year-over-year; reported operating profit rose 60%.

• Efficiency programs delivered JPY 200 billion in annualized savings, impacting ~3,000 positions and supporting profitability and R&D reinvestment.

• Pipeline momentum accelerated, with six phase III programs underway, positive late-stage data readouts, and key regulatory approvals for Entyvio, Qdenga, Fruzaqla, and others.

• Dividend increased to JPY 200 per share, reflecting strong cash flow and commitment to shareholder returns.

Financial highlights

• Reported revenue reached JPY 4,581.6 billion, up 7.5% year-over-year; core revenue up 7.4% at actual FX.

• Core operating profit was JPY 1,162.6 billion, up 10.2% at actual FX; reported operating profit grew 60%.

• Core EPS was JPY 491 (+1.5%), reported EPS JPY 68 (-25.8%), both impacted by higher tax expenses.

• Free cash flow was JPY 769 billion, exceeding forecasts due to lower CapEx and higher operating profit.

• Leverage ratio improved to 2.8x adjusted net debt/EBITDA as of March 2025.

Outlook and guidance

• FY2025 guidance: broadly flat core revenue, core operating profit, and core EPS at constant exchange rate; reported revenue forecast JPY 4,530.0 billion (-1.1% year-over-year).

• Growth and launch products expected to exceed 50% of total revenue, offsetting Vyvanse erosion.

• Free cash flow outlook stable at JPY 750–850 billion; dividend to rise to JPY 200 per share.

• Guidance does not include potential tariff impacts; exposure believed to be limited.

• Operating profit expected to rise 38.7% to JPY 475.0 billion, with net profit projected to more than double to JPY 228.0 billion.